IPS Portal

What IPS Portal does

iPS Portal Inc. (株式会社iPSポータル) is a Kyoto-based biotechnology company founded in 2014 as a spin-off from iPS Academia Japan, with deep institutional ties to Kyoto University and its Center for iPS Research and Application (CiRA). The company operates an integrated Cell-Tech platform organized around six service modules: (1) Bio-Resource Reserve (BRR), an autologous iPS cell manufacturing and lifetime storage service for healthy individuals; (2) Technology / Research Support and Contract Testing, including iPS cell establishment from fibroblasts and PBMC, paper-reproduction differentiation, drug screening, and bioinformatics analysis; (3) Development Support, evaluating cell culture equipment, reagents, and analytical devices for life sciences manufacturers; (4) Education and Training programs for iPS cell culture technicians and business managers; (5) Business Support for companies entering life sciences; and (6) Regenerative Medicine consulting covering regulatory affairs, PMDA submissions, and GMP facility design. Its technology stack combines episomal vector reprogramming, licensed CRISPR-Cas3 genome editing from C4U, and a portfolio of disease-specific patient-derived iPS cell lines (Alzheimer's, Parkinson's, Werner syndrome).

The company sells primarily B2B via direct inquiry-based sales to pharmaceutical companies, biotech startups, medical device manufacturers, cosmetics companies, and functional food companies in Japan, with custom-priced contract engagements and multi-year business support subscriptions. The BRR service, accepting advance reservations from April 2026 with manufacturing beginning autumn 2026, introduces a direct-to-consumer subscription model that diversifies the revenue base. iPS Portal is backed by a broad consortium of 22+ Japanese strategic corporate shareholders including Shimadzu, Eisai, Ajinomoto, Sysmex, Chugai, Horiba, NTT Data, Exedy, and Daiwa Securities, plus institutional investors Nippon Life Insurance and SMBC, with Kyoto Prefecture and Kyoto City as government shareholders. Stated capital including reserves stands at 1,242 million JPY, headcount is approximately 20 employees, and the company operates from the Louis Pasteur Center for Medical Research in Kyoto.

Name

IPS Portal

Legal name

株式会社iPSポータル

Website

https://ipsportal.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

iPS Portal is a Kyoto-based iPS cell technology platform founded in 2014 that provides contract testing, research support, regenerative medicine consulting, and training to pharmaceutical, biotech, cosmetics, and life sciences companies in Japan, and is launching a consumer autologous iPS cell banking service (BRR) in 2026.

Ownership category

akta.pro rank

Headquarters

HQ city

Kyoto

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Contract Testing Services: Research and contract testing services for drug discovery, regenerative medicine, cosmetics, and functional foods using iPS cells and differentiated cells. Includes screening assays, differentiation protocols, and quality testing.
2. Regenerative Medicine Support: Pharmaceutical affairs consulting, approval application support, facility design consulting, and regulatory compliance services for regenerative medicine product development.
3. Education and Training: iPS cell culture training programs, online seminars, and customized education services for researchers and business professionals entering the life sciences field.
4. Business Support Services: Market research, business planning, technology evaluation, and commercialization support for companies entering the life sciences field.
5. Bio-Resource Reserve (BRR): Autologous iPS cell manufacturing and lifetime storage service for future medical treatment. Plans to accept advance reservations from April 2026.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

IPS Portal provides contract testing and research support services using induced pluripotent stem (iPS) cells, including iPS cell establishment, directed differentiation into multiple cell types, screening assays, and bioinformatics analysis for pharmaceutical, biotech, cosmetics, and food companies. The company also offers regenerative medicine regulatory and commercialization consulting, training programs, and the Bio-Resource Reserve (BRR) autologous iPS cell manufacturing and storage service for future medical use.

Product overview

iPS Portal operates as a platform of six integrated service modules centered on Cell-Tech, encompassing iPS cells and genome editing technology. The core offering is the Bio-Resource Reserve (BRR) service for autologous iPS cell manufacturing and storage, supported by Research Support and Contract Testing Services (iPS cell establishment, paper reproduction testing, screening, bioinformatics), Development Support Services (culture product and equipment evaluation), Education/Training Services, Business Support Services, and Regenerative Medicine Related Services (technology introduction, development, regulatory affairs).

Differentiator

Problem solved

Functional benefit

Products and services

• Bio-Resource Reserve (BRR) Autologous iPS cell manufacturing and lifetime storage service that creates and stores high-quality iPS cells from a person's own healthy cells to prepare for future diseases and medical treatments, and to reduce manufacturing burden on treatment product developers.
• Research Support and Contract Testing Services (Technology) Contract research and testing services for drug discovery, regenerative medicine, cosmetics, and functional foods delivered by a science fellow and expert experimental team using iPS cells and differentiated cell types.
• Development Support Services

Quantifiable outcome

• Successfully established and provided various disease-specific iPS cell lines including 11 Alzheimer's disease, 6 Parkinson's disease, and 1 Werner syndrome patient-derived lines
• +2 more outcomes

Named customers8 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• NTT DatacoreStrategic or Co-development Partner · 23 December 2025Capital and business partnership for BRR (Bio-Resource Reserve) data platform development and information security infrastructure. NTT Data will leverage its expertise in security technology and PHR (Personal Health Record) management to build a robust data platform for autologous iPS cell storage business.
• Stem Cell InstitutecoreStrategic or Co-development Partner · 30 September 2025Joint research contract for autologous iPS cell banking service from cord blood. Aims to realize iPS cell manufacturing and storage services from stored cord blood, targeting clinical utilization of autologous cord blood-derived iPS cells.
• C4U CorporationcoreTechnology or Integration · 28 September 2021Patent license agreement for CRISPR-Cas3 genome editing technology for contract services. Enables provision of genome-edited cells (cell lines, iPS cells) tailored to customer needs, and expansion of contract testing menu including disease patient iPS cells and control cells for differentiation and screening.
• Raymei Inc.coreOthersRelated company (associated enterprise) specializing in corneal regenerative medicine. iPS Portal has supported the company since its establishment in 2016. Raymei announced clinical research results for allogeneic iPS cell-derived corneal epithelial cell sheet transplantation published in Lancet.
• Houjou Inc.minorOthersRelated company (associated enterprise) aiming to protect endangered species and commercialize fertility treatments, established in 2020.
• Kyoto University / CiRAcoreStrategic or Co-development PartnerSpin-off company from Kyoto University with ongoing academic connections. Scientific advisory board includes CiRA Professor Kenji Osafune. Company history indicates transfer of operations from iPS Academia Japan related to non-patent operations.
• Ministry of Health, Labour and Welfare (Japan)coreOthersGrant recipient for 'Hyakumanpen iPS Drug Discovery Crossroad' project under the Drug Discovery Cluster Campus Project. Project aims to create an incubation facility for startup and drug discovery companies with iPS cell support services.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Market position

Strengths4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/iPSportal.inc
• Xx.com/iPSC_portal

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries2 records

Funding overview

Funding rounds5 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IPS Portal